Stevie Threatt

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial”.

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

The Lancet Child & Adolescent Health(2023)10.1016/s2352-4642(23)00031-7

N/A

1.2DataRank · unranked

48 citations

Daniel Landi, Michael C. Brown, Henry S. Friedman, Roger E. McLendon, James E. Herndon +15 more

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2566

N/A

0DataRank · unranked

5 citations

Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret Johnson, Stevie Threatt +10 more

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e14015

N/A

0DataRank · unranked

10 citations

Vidyalakshmi Chandramohan, Daniel Landi, Margaret Johnson, Mustafa Khasraw, Katherine B. Peters +12 more